A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Key Inclusion Criteria:

• Histologically or cytologically documented squamous or non-squamous NSCLC.

• Stage IV NSCLC (according to Version 8 of the IASLC Staging Manual in ThoracicOncology 2016), not amenable to curative surgery or radiation.

• Absence of sensitizing EGFR mutations and ALK and ROS1 rearrangements.

• Absence of documented tumor genomic alteration results from tests conducted as partof standard local practice in any other actionable driver oncogenes for which thereare locally approved targeted first-line therapies.

Key Exclusion Criteria:

• Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant. Raresubtypes are excluded.

• Spinal cord compression.

• Symptomatic brain metastases. Brain metastases may be treated or untreated, butparticipants must be asymptomatic and off steroids for at least 14 days prior tostart of study intervention. A minimum of 2 weeks must have elapsed between the endof whole brain radiotherapy and study enrollment.

• History of another primary malignancy except for:

1. Malignancy treated with curative intent with no known active disease ≥ 2 yearsbefore the first dose of study intervention and of low potential risk forrecurrence.

2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidenceof disease.

3. Adequately treated carcinoma in situ without evidence of disease.

• As judged by the investigator, any condition that would interfere with evaluation ofthe study intervention or interpretation of participant safety or study results.